Amplia Therapeutics is developing a class of drug called a FAK inhibitor. If you have been diagnosed with pancreatic cancer you may be eligible to participate in our clinical trial.
Amplia is developing a class of drug called a FAK inhibitor which we hope will make cancers more vulnerable and responsive to currently used treatments.
Amplia has successfully navigated vital research and development milestones to get to this stage. Our clinical trial sites in Australia and South Korea are now recruiting people with pancreatic cancer for our ACCENT trial to test if narmafotinib in combination with standard of care drugs gemcitabine and nab-paclitaxel (also known as Abraxane®) is effective in treating cancer.
The ACCENT Clinical Trial (AMP945-PC-201) has strict entry criteria. Please note, Amplia is not recruiting patients directly and all enquiries for involvement must be made via our clinical trial sites.
The trial is now open for recruitment.
Clinical trial sites are located in Brisbane, Sydney and Melbourne, Australia and South Korea. See below.
The ACCENT trial will test if narmafotinib helps people with pancreatic cancer have a better response to standard of care chemotherapies, gemcitabine and nab-paclitaxel.
Narmafotinib aims to break down the fibrotic tissue shield in pancreatic cancer to allow the chemotherapy to be more effective.
If you have been diagnosed with pancreatic cancer you may be eligible to participate.
There are many criteria to join a clinical trial. You should discuss your eligibility directly with your oncologist.
Some things to consider: